Thomson Reuters, a distinguished brokerage company, has placed a 52-week price target of $140.83 on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) shares after it surveyed top market analysts. Calculating estimated earnings after taking into consideration different elements, it is predicted to come at $3.45 for the next fiscal and $N/A for underway quarter.
Analysts take into account the price to earnings ratio to estimate the firm’s valuation. This ratio, which is also called as the P/E ratio evaluates the company on relative expense factor. The formula to calculate ratio is stock’s latest price/ per share earnings. The P/E ratio of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) stands at 9.92.
Analysts also work out Price/Earnings Growth ratio in an attempt to estimate the valuation of a firm. This ratio commonly known as the PEG ratio implies the stock’s valuation compared to earnings growth potential. Investors look to invest in the stocks with a lower PEG ratio. For Ligand Pharmaceuticals Incorpor, the PEG ratio for coming 3-5 years is 0.65.
The technical analysis highlights that Ligand Pharmaceuticals Incorpor current is trading $-15.16 points away or -12.60% from its 50-day moving average of $120.35. Further it is trading $-9.50 or -8.28% away its 200-day moving average of $114.69.
The 52-week high of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was $139.79 while lowest point recorded in 52-week was $79.66. It implies if stock price makes a movement of over $-34.60, it will record a new 52-week high. In the case of +32.05% drop, it will touch a new 52-week low.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...